Literature DB >> 29018927

Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now.

Massimo Galia1, Domenico Albano2, Corrado Tarella3, Caterina Patti4, Luca Maria Sconfienza5,6, Antonino Mulè4, Pierpaolo Alongi7, Massimo Midiri1, Roberto Lagalla1.   

Abstract

ᅟ: The indolent non-Hodgkin lymphomas (i-NHLs) are characterised by 'indolent' clinical behaviour with slow growth and prolonged natural history. The watchful waiting (WW) strategy is a frequently employed treatment option in these patients. This implies a strict monitoring by imaging examinations, including 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) and CT. A major concern is radiation exposure due to regularly monitoring by conventional imaging procedures. Several studies have demonstrated the reliability of whole-body magnetic resonance imaging (WB-MRI) for lymphoma staging. WB-MRI could be useful for active surveillance in i-NHLs providing the suspect of disease progression that can be then confirmed by additional diagnostic procedures, including 18F-FDG-PET/CT. The directive 2013/59 by the European Union claims that if a radiation-free imaging technique allows obtaining the same diagnostic results, it should be invariably used. In this setting, WB-MRI may be considered a reasonable option in i-NHLs under WW, replacing imaging modalities that cause exposure to ionising radiations. This will help to reduce the cancer risk in i-NHL patients for whom chemo-/radiotherapy remain the usual treatment options following the usually long WW phase. The scientific community should raise the awareness of the risk of ionising radiations in i-NHLs and the emphasise the need for establishing the proper place of WB-MRI in lymphoma imaging. KEY POINTS: • Watchful waiting is a reasonable option in patients with indolent non-Hodgkin lymphomas. • Imaging is crucial to monitor patients with indolent non-Hodgkin lymphomas. • CT and 18 F-FDG-PET/CT are commonly used, implying a substantial radiation exposure. • WB-MRI is highly reliable in lymphoma staging. • WB-MRI may be considered to monitor indolent non-Hodgkin lymphomas under watchful waiting.

Entities:  

Keywords:  Ionising radiation; Lymphoma; Magnetic resonance imaging; Watchful waiting; Whole body imaging

Mesh:

Year:  2017        PMID: 29018927     DOI: 10.1007/s00330-017-5071-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  41 in total

1.  Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Taoufik El-Gnaoui; Alexandre Vignaud; Pauline Beaussart; Shih-jui Lin; Karim Belhadj; Pierre Brugières; Eva Evangelista; Corinne Haioun; Michel Meignan; Alain Rahmouni
Journal:  Eur Radiol       Date:  2010-03-23       Impact factor: 5.315

Review 2.  Optimal management of older patients with chronic lymphocytic leukemia: some facts and principles guiding therapeutic choices.

Authors:  Tamar Tadmor; Aaron Polliack
Journal:  Blood Rev       Date:  2011-09-28       Impact factor: 8.250

Review 3.  Computed tomography--an increasing source of radiation exposure.

Authors:  David J Brenner; Eric J Hall
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

Review 4.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

5.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

6.  The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

Authors:  S Luminari; I Biasoli; L Arcaini; A Versari; C Rusconi; F Merli; M Spina; A J M Ferreri; P L Zinzani; A Gallamini; S Mastronardi; C Boccomini; G Gaidano; A M D'Arco; F Di Raimondo; A M Carella; A Santoro; P Musto; M Federico
Journal:  Ann Oncol       Date:  2013-04-12       Impact factor: 32.976

Review 7.  Management of indolent lymphoma: where are we now and where are we going.

Authors:  Matthew A Lunning; Julie M Vose
Journal:  Blood Rev       Date:  2012-10-09       Impact factor: 8.250

8.  SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.

Authors:  Pier Luigi Zinzani; Monia Marchetti; Atto Billio; Giovanni Barosi; Angelo Michele Carella; Mario Lazzarino; Maurizio Martelli; Alessandro Rambaldi; Luigi Rigacci; Corrado Tarella; Umberto Vitolo; Sante Tura
Journal:  Am J Hematol       Date:  2013-01-22       Impact factor: 10.047

9.  Splenic marginal zone lymphoma: a prognostic model for clinical use.

Authors:  Luca Arcaini; Mario Lazzarino; Nora Colombo; Sara Burcheri; Emanuela Boveri; Marco Paulli; Enrica Morra; Marcello Gambacorta; Sergio Cortelazzo; Alessandra Tucci; Marco Ungari; Achille Ambrosetti; Fabio Menestrina; Lorella Orsucci; Domenico Novero; Alessandro Pulsoni; Maurizio Frezzato; Gianluca Gaidano; Daniele Vallisa; Viviana Minardi; Claudio Tripodo; Vincenzo Callea; Luca Baldini; Francesco Merli; Massimo Federico; Vito Franco; Emilio Iannitto
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

10.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk.

Authors:  Bingsheng Huang; Martin Wai-Ming Law; Pek-Lan Khong
Journal:  Radiology       Date:  2009-02-27       Impact factor: 11.105

View more
  6 in total

1.  Renal endometriosis mimicking complicated cysts of kidney: report of two cases.

Authors:  D Giambelluca; D Albano; E Giambelluca; A Bruno; F Panzuto; A Agrusa; G Di Buono; F Cannizzaro; Cesare Gagliardo; M Midiri; R Lagalla; G Salvaggio
Journal:  G Chir       Date:  2017 Sep-Oct

2.  Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey.

Authors:  Domenico Albano; Alessandro Stecco; Giuseppe Micci; Luca Maria Sconfienza; Stefano Colagrande; Alfonso Reginelli; Roberto Grassi; Alessandro Carriero; Massimo Midiri; Roberto Lagalla; Massimo Galia
Journal:  Radiol Med       Date:  2020-06-22       Impact factor: 3.469

Review 3.  MRI and PET/MRI in hematologic malignancies.

Authors:  Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder
Journal:  J Magn Reson Imaging       Date:  2019-07-01       Impact factor: 4.813

4.  Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients.

Authors:  Gil-Sun Hong; Eun Jin Chae; Jin-Sook Ryu; Sun Young Chae; Hyo Sang Lee; Dok Hyun Yoon; Cheolwon Suh
Journal:  Cancer Imaging       Date:  2021-01-07       Impact factor: 3.909

Review 5.  Imaging features of adrenal masses.

Authors:  Domenico Albano; Francesco Agnello; Federico Midiri; Giusy Pecoraro; Alberto Bruno; Pierpaolo Alongi; Patrizia Toia; Giuseppe Di Buono; Antonino Agrusa; Luca Maria Sconfienza; Salvatore Pardo; Ludovico La Grutta; Massimo Midiri; Massimo Galia
Journal:  Insights Imaging       Date:  2019-01-25

Review 6.  Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma.

Authors:  Domenico Albano; Giuseppe Micci; Caterina Patti; Federico Midiri; Silvia Albano; Giuseppe Lo Re; Emanuele Grassedonio; Ludovico La Grutta; Roberto Lagalla; Massimo Galia
Journal:  Diagnostics (Basel)       Date:  2021-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.